

Optimizing Antithrombotic Therapy in Atrial Fibrillation



EXPERTS ON THE CASE!

Thursday, October 24th, 2019 • 12:30 – 1:30 pm
Palais des congrès, Room 517 D • Montreal, QC
A buffet lunch will be served

Faculty

CO-CHAIRS:

Jason G. Andrade, MD, FRCPC

Associate Professor,
University of British Columbia
Vancouver General Hospital

Laurent Macle, MD, FRCPC, FHRS

Cardiac electrophysiologist,
Professor of Medicine,
Université de Montréal
Chief of the electrophysiology service,
Montreal Heart Institute

PRESENTERS:

Paul Dorian, MD, MSc, FRCPC

Dexter H.C. Man Chair in Cardiology,
Department Director, Division of Cardiology
Staff Cardiac Electrophysiologist,
St. Michael's Hospital
Professor of Medicine,
Division of Cardiology and Division of Clinical
Pharmacology,
University of Toronto

Shaun Goodman, MD

Co-director of the Canadian VIGOUR Centre
(CVC)
Adjunct Professor, Department of Medicine,
University of Alberta
Staff Cardiologist, Associate Head, Division
of Cardiology, Department of Medicine,
St. Michael's Hospital, Toronto
Professor and Heart & Stroke Foundation
of Ontario Chair, Department of Medicine,
University of Toronto
Consultant, Canadian Heart Research Centre

Isabelle Nault, MD, FRCPC

Cardiac Electrophysiologist,
IUCPQ Quebec

Agenda

| | |
|------------------|---|
| 12:30 – 12:35 pm | Opening remarks Dr. Laurent Macle |
| 12:35 – 12:50 pm | Oral anticoagulation in ACS/PCI Dr. Shaun Goodman |
| 12:50 – 1:05 pm | Question period Moderated by Dr. Laurent Macle and Dr. Jason Andrade |
| 1:05 – 1:15 pm | Anticoagulation management in the complex, elderly patient Dr. Isabelle Nault |
| 1:15 – 1:25 pm | Anticoagulation management in patients with a risk of GI bleeding Dr. Paul Dorian |
| 1:25 – 1:30 pm | Question period Moderated by Dr. Laurent Macle and Dr. Jason Andrade |
| 1:30 pm | Closing remarks/adjourn Dr. Laurent Macle |

Learning Objectives

At the end of this session, participants will be able to:

- Identify the optimal antithrombotic treatment strategy for AF patients with ACS/PCI.
- Describe the efficacy and safety of oral anticoagulation therapy for stroke prevention in AF patients at higher risk of stroke and bleeding.
- Describe the evidence supporting the different combinations of oral anticoagulants and antiplatelet agents for AF patients in the context of ACS or PCI.
- Identify the risks and benefits of oral anticoagulation therapy for the complex elderly AF patient.
- Examine the optimal stroke-prevention strategy for AF patients at higher risk or with a history of bleeding.

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and the BMS/Pfizer Alliance and was planned to achieve scientific integrity, objectivity and balance.



Canadian Cardiovascular Society

Leadership. Knowledge. Community.

Société canadienne de cardiologie

Communauté. Connaissances. Leadership.



**CANADIAN
CARDIOVASCULAR
CONGRESS**

**CONGRÈS CANADIEN
SUR LA SANTÉ
CARDIOVASCULAIRE**

This program was made possible through an educational grant from the BMS/Pfizer Alliance.



Bristol-Myers Squibb

